Janux Therapeutics JANX Accrued Liabilities, Current
Accrued Liabilities, Current at other companies
Other financials
Where this comes from
Reported directly by Janux Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Janux Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Janux Therapeutics's accrued liabilities, current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Janux Therapeutics's accrued liabilities, current?
- Janux Therapeutics (JANX) reported accrued liabilities, current of $15.48M in Q1 2026.
- How has Janux Therapeutics's accrued liabilities, current changed year-over-year?
- Janux Therapeutics's accrued liabilities, current increased by 16.0% year-over-year, from $13.34M to $15.48M.
- What is the long-term trend for Janux Therapeutics's accrued liabilities, current?
- Over 5 years (2020 to 2025), Janux Therapeutics's accrued liabilities, current has grown at a 88.0% compound annual growth rate (CAGR), from $751K to $17.63M.